Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck by Kim, J G et al.
Phase II study of concurrent chemoradiotherapy with capecitabine
and cisplatin in patients with locally advanced squamous cell
carcinoma of the head and neck
JG Kim
1, SK Sohn
1, DH Kim
1, JH Baek
1, SB Jeon
1, YS Chae
1, KB Lee
1, JS Park*,2, JH Sohn
2, JC Kim
3 and IK Park
3
1Department of Oncology/Hematology, Kyungpook National University, College of Medicine, Kyungpook National University Hospital, Daegu, Korea;
2Department of Otorhinolaryngology, Kyungpook National University, College of Medicine, Kyungpook National University Hospital, Daegu, Korea;
3Department of Radiation Oncology, Kyungpook National University, College of Medicine, Kyungpook National University Hospital, Daegu, Korea
We aimed to evaluate the efficacy and safety of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally
advanced squamous cell carcinoma of the head and neck (SCCHN). In total, 37 patients with stage III or IV SCCHN were enrolled on
the study. The chemotherapy consisted of two cycles of intravenous cisplatin of 80mgm
 2 on day 1 and oral capecitabine
825mgm
 2 twice daily from day 1 to day 14 at 3-week intervals. The radiotherapy (1.8–2.0Gy 1 fractionday
 1 to a total dose of
70–70.2Gy) was delivered to the primary tumour site and neck. The primary tumour sites were as follows: oral cavity (n¼6),
oropharynx (n¼11), hypopharynx (n¼8), larynx (n¼3), nasopharynx (n¼6), and paranasal sinus (n¼3). After the
chemoradiotherapy, 29 complete responses (78.4%) and 6 partial responses (16.2%) were confirmed. Grade 3 or 4 neutropenia
occurred only in two patients, plus grade 3 febrile neutropenia was observed only in one patient. At a median follow-up duration of
19.8 months, the estimated overall survival and progression-free survival rate at 2-year was 76.8 and 57.9%, respectively. Concurrent
chemoradiotherapy with capecitabine and cisplatin was found to be well tolerated and effective in patients with locally advanced
SCCHN.
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The majority of patients with squamous cell carcinoma of the head
and neck (SCCHN) present a locoregionally advanced disease,
which is associated with a poor prognosis despite treatment with
surgical resection or radiation, or both (Vokes et al, 1993). Since
the effects of treatment on functional abilities, such as speech and
eating, are additional factors to consider in patients with SCCHN,
recent attempts to improve the major end points of treatment
(local control, organ preservation, and overall survival) have
focused on the use of radiotherapy with concurrent chemotherapy
(Brizel et al, 1998; Wendt et al, 1998; Calais et al, 1999; Pignon
et al, 2000). Generally, cisplatin combined with 5-fluorouracil (5-
FU) have been considered as one of standard regimen for
concurrent chemoradiotherapy (Browman et al, 1994; Brizel
et al, 1998; Wendt et al, 1998; Calais et al, 1999). However, the
adverse effects of 5-FU, such as oral mucositis, which is an additive
complication to radiation, or bone marrow suppression, can result
in treatment-related hospitalisation or mortality, thereby compro-
mising the quality of life and compliance to treatment (Wendt
et al, 1998).
The oral fluoropyrimidine capecitabine (Xeloda
s; Hoffmann-La
Roche) was rationally designed to preferentially generate 5-FU in
tumour tissue and mimic continuous-infusion 5-FU. This tumour
selectivity is achieved through exploiting the significantly higher
activity of thymidine phosphorylase (TP) in many tumour tissues
compared with healthy tissue (Miwa et al, 1998; Schuller et al,
2000). The expression of this enzyme is enhanced in tumour areas
with poor perfusion, hypoxia, and acidosis, a situation found in
most advanced HNSCC. Moreover, there is evidence that radiation
leads to the upregulation of TP expression (Sawada et al, 1999). In
a preclinical study, capecitabine given orally resulted in consis-
tently higher tissue-to-plasma 5-FU concentration ratios than 5-FU
administered intravenously (Ishikawa et al, 1998). In addition,
capecitabine has also exhibited antitumour activity when given as
a monotherapy or in combination with cisplatin in patients with
various solid tumours as well as in advanced HNSCC (Blum et al,
1999; Van Cutsem et al, 2001; Kim et al, 2002; Pivot et al, 2003;
Park et al, 2004).
Furthermore, since the key side effects of capecitabine are
hand–foot syndrome and diarrhoea, which overlap little with the
side effects of cisplatin or radiation, capecitabine can be a good
chemotherapeutic agent in concurrent chemoradiotherapy for
SCCHN.
Accordingly, the current phase II study was conducted to
evaluate the efficacy and safety of concurrent chemoradiotherapy
with capecitabine and cisplatin for locally advanced SCCHN.
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Eligibility
All the patients involved in the current study had measurable,
histologically or cytologically confirmed, locoregionally advanced
stage III or IV SCCHN arising from the oral cavity, pharynx,
larynx, or paranasal sinuses. The patients were 20–75 years of age
with a performance status of 0–2 on the Eastern Cooperative
Oncology Group (ECOG) scale. Plus, adequate haematological
(WBC count X4 10
9l
 1, platelet count X100 10
9l
 1, haemo-
globin X9gdl
 1), renal (serum creatinine p1.5mgdl
 1 and
creatinine clearance X50mlmin
 1), and hepatic (total bilirubin
p2.0mgdl
 1 and serum transaminase level p3 times the upper
limit of the normal range) levels were also required. Patients were
ineligible if they had previously received chemotherapy or
radiation therapy, or had other severe medical illnesses, distant
metastasis, another active malignancy in the last 5 years, except
treated nonmelanoma skin cancer or cervical dysplasia, or a
history of anaphylaxis to drugs. The institutional review board of
the authors’ institution approved the protocol, and written
informed consent was obtained from all patients before enroll-
ment.
Study treatment
The administration schedule is shown in Figure 1. Capecitabine
825mgm
 2 b.i.d with pyridoxine 100mg t.i.d was given on days
1–14, followed by a 7-day rest period. The capecitabine was
supplied as film-coated tablets at two dose strengths, 150 and
500mg, while the cisplatin 80mgm
 2 was administered through a
1-h intravenous infusion on the first day of each cycle. Pre- and
post intravenous hydration and appropriate antiemetics were also
administered to prevent renal toxicity and emesis. Two cycles of
chemotherapy were repeated every 3 weeks.
Radiotherapy (1.8–2.0Gy 1 fractionday
 1 to a total dose of 70–
70.2Gy), administered 5 days per week, was delivered to the
primary tumour site and neck, and was targeted to begin on the
first day of chemotherapy. Patients underwent a complete dental
evaluation and treatment as early as possible before the initiation
of radiotherapy. Every effort was made to continue the radiation
on schedule.
Dose modification
The protocol plan was to continue the study treatment despite
mucositis or dermatitis. However, if grade 3 or 4 capecitabine-
related haematological or nonhaematological toxicity, such as
diarrhoea and hand–foot syndrome, occurred (not including
radiation-related toxicity), capecitabine was withheld until the
toxicity had improved by at least two grade levels. Subsequent
capecitabine doses then required a 20% dose reduction. The dose
of cisplatin was reduced to 50% if the calculated creatinine
clearance level was 30–50mlmin
 1. No cisplatin was administered
if the creatinine clearance level was less than 30mlmin
 1. In the
presence of myelosuppression (WBC counto 4 10
9l
 1 or platelet
count o100 10
9l
 1), a persisting fever that exceeded 381C, or
other clinically apparent infections, a cycle could be postponed for
1 week or interrupted if this was judged to be necessary in the
opinion of the attending physicians.
Surgery
Salvage surgery of the primary tumour site was recommended for
operable patients with a respectable disease, who failed to achieve
a complete response (CR) after the end of the chemoradiotherapy.
The extent of surgery varied, ranging from laser resection or a wide
excisional biopsy to a complete resection of the oral cavity or
tonsillar primary. A modified neck dissection could also be
performed. The surgery was carried out routinely 6–8 weeks after
the chemoradiotherapy.
Study assessments
Before being enrolled on the trial, all patients underwent a full
medical history and physical examination, blood tests, computed
tomography (CT) or magnetic resonance imaging of the head and
neck, and chest X-ray (CT of the chest if the patient’s low neck
nodes were involved). Assessment of the tumour response by
clinical examination and CT scanning took place 6 weeks after
completing the chemoradiation therapy. A biopsy or fine needle
aspiration cytology to determine the pathologic response was not
routinely performed. The definitions of CR, partial response (PR),
stable disease (SD), and progressive disease (PD) were based on
the standard definitions established by the WHO (1979). The
patients were monitored for toxicity (medical interview, physical
examination, and complete blood count) throughout the treat-
ment. Complete blood counts and chemistry were performed every
week until the end of the chemoradiotherapy. Systemic toxicity
resulting from treatment was graded according to the National
Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0.
Acute radiation toxicities were graded according to the European
Organization Therapy Oncology Group (EORTC-RTOG) toxicity
criteria. Hand–foot syndrome was graded 1–3, as defined in
previous capecitabine clinical studies (Blum et al, 1999).
Statistical analysis
As a phase II study, the primary end point was to evaluate the
response rate, while toxicity, progression, and overall survival were
the secondary end points. For sample size calculation, the current
trial used a two-stage optimal design, as proposed by Simon
(1989), with a 90% power to accept the hypothesis and 5%
significance to reject the hypothesis. Plus, the current trial was
designed to detect a response rate of 90% as compared to a
minimal, clinically meaningful response rate of 70%. Allowing for
a follow-up loss rate of 10%, the total sample size was 36 patients
with a measurable disease. Time to progression was measured as
the time from the initiation of therapy until death of disease or
toxicity, appearance of new lesions, or a greater than 25% increase
of the indicator lesions over the previous smallest size. Overall
survival was measured from the initiation of therapy to the date of
the last follow-up or any cause of death. Progression-free and
overall survival analyses were all estimated using the Kaplan–
Meier method. The statistical data were obtained using an SPSS
software package (SPSS 11.0 Inc. Chicago, IL, USA).
Day 1 2 3. . . . . 14 . . . .  22 21 . . . . 
First cycle Second cycle
Cisplatin i.v.
Capecitabine P.O.
Irradiation: 70 – 70.2 Gy
Figure 1 Administration schedule of concurrent chemoradiotherapy
with capecitabine and cisplatin in patients with squamous cell carcinoma of
the head and neck. i.v: intravenous; PO: per oral.
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Patient characteristics
A total of 37 patients were enrolled in the current study from April
2003 to May 2004 at Kyungpook National University Hospital,
Daegu, Korea. The characteristics of the patients are summarised
in Table 1. The median age of the patients was 61.0 years (range,
35–75 years), and 31 (83.8%) patients were male. Most of the
patients (89.2%) had a good performance status (ECOG 1). The
primary sites of the tumours were as follows: oral cavity (n¼6),
oropharynx (n¼11), hypopharynx (n¼8), larynx (n¼3), naso-
pharynx (n¼6), and paranasal sinus (n¼3). A total of 22 patients
(59.5%) had a stage III disease, while the remaining 15 patients
were stage IV. In all, 16 patients (43.2%) had an N2 (n¼15) or N3
(n¼1) status before treatment.
Response and survival
Of the 37 patients, 34 (91.2%) completed the planned treatment,
with the remaining three being lost to follow-up or patient refusal.
All efficacy data are reported using the intent-to-treat patient
population. After the chemoradiotherapy, 29 CRs (78.4%) and 6
PRs (16.2%) were confirmed, giving an overall clinical response
rate of 94.6% (95% CI; 87.0–102.2%). The primary site CR was
80.0% (28 out of 35) and metastatic lymph node CR was 70.4% (19
out of 27) (Table 2). Four out of six patients with nasopharyngeal
tumour showed CR and remaining two patients PR. Among the
eight patients who failed to achieve CR after the chemoradiother-
apy, three patients underwent surgery and two patients received
salvage chemotherapy. At the time of the present evaluation, 13
patients had developed disease progression or recurrence (five –
primary tumour, three – regional lymph node, two – both primary
tumour and regional lymph node, and three – distant metastases to
the bone), and seven patients had died of disease progression. The
median survival time had not yet been reached at a median follow-
up duration of 19.8 months (range, 3.1–27.5 months), while the
estimated overall survival and progression-free survival rate at 2-
year was 76.878.5 and 57.9711.1%, respectively (Figure 2).
Table 1 Patient characteristics
Characteristic Number of patients, N¼37 (%)
Age (years)
Median (range) 61 (35–75)
Male/female 31 (83.8)/6 (16.2)
ECOG performance status
1 33 (89.2)
2 4 (10.8)
Site of primary tumour
Oral cavity 6 (16.2)
Oropharynx 11 (29.7)
Hypopharynx 8 (21.6)
Larynx 3 (8.1)
Paranasal sinus 3 (8.1)
Nasopharynx 6 (16.2)
Histologic classification
Well differentiated 8 (21.6)
Moderately differentiated 10 (27.0)
Poorly or undifferentiated 11 (29.7)
Unspecified 8 (21.6)
Stage
III 22 (59.5)
IV 15 (40.5)
T classification
T1 3 (8.1)
T2 15 (40.5)
T3 13 (35.1)
T4 6 (16.2)
N classification
N0 9 (24.3)
N1 12 (32.4)
N2 15 (40.5)
N3 1 (2.7)
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
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Figure 2 Progression-free survival (A) and overall survival (B) for all
patients.
Table 2 Tumour response (intent-to-treat analysis, N¼37)
Response (%)
Variable CR PR SD PD Response rate
Primary site 28/35 (80.0) 5/35 (14.3) 2/35 (5.7) 0/35 33/35 (94.3)
Lymph nodes 19/27 (70.4) 5/27 (18.5) 2/27 (7.4) 1/27 (3.7) 24/27 (88.9)
Overall 29/37 (78.4) 6/37 (16.2) 1/37 (2.7) 1/37 (2.7) 35/37 (94.6)
CR¼complete response; PR¼partial response; SD¼stable disease; PD¼progres-
sive disease.
CCRT with capecitabine/cisplatin in SCCHN
JG Kim et al
1119
British Journal of Cancer (2005) 93(10), 1117–1121 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sLocoregional control rate of the disease at 2-year was 72.677.4%.
For the patient group except those with nasopharyngeal tumor, the
estimated overall survival and progression-free survival rate at 2-
year was 81.379.8 and 74.277.9%, respectively.
Toxicity
All 37 patients were assessable for toxicity. The haematologic and
nonhaematologic toxicities that occurred during the current study
are summarised in Table 3. The most severe haematologic adverse
event was neutropenia, which occurred with a grade 3/4 intensity
in two patients (5.4%). Plus, grade 3 febrile neutropenia was
observed in one patient (2.7%). Although this case was successfully
treated with antibiotics and G-CSF, the patient withdrew their
consent after this experience. No treatment-related death occurred
during this study. Mucositis and dermatitis, as expected from a
combination of radiation with an effective chemotherapeutic-
sensitising agent, were the most common nonhaematological
toxicities. Grade 3/4 mucositis and dermatitis was observed in 67.6
and 24.3%, respectively. Grade 2 hand–foot syndrome, a
complication of capecitabine, occurred only in four patients
(10.8%). The dose of capecitabine was reduced in two cycles due to
neutropenia or diarrhoea, and cisplatin omitted from one cycle
because of nephrotoxicity. The second cycle of chemotherapy was
delayed in nine patients for the following reasons: haematological
toxicity (n¼7), persistent fever (n¼1), and patient refusal (n¼1).
The dose intensity of capecitabine and cisplatin was well
maintained throughout the study cycles.
DISCUSSION
Many studies have demonstrated chemotherapy and radiotherapy
to be highly effective in increasing the survival of patients with an
unresectable disease. Moreover, concurrent chemoradiotherapy
and induction chemotherapy have been established as an
appropriate standard of care for patients with locally advanced
SCCHN. However, no standard concurrent chemoradiotherapy
regimen has been defined.
Therefore, the present phase II study was designed to evaluate
the efficacy and toxicity of capecitabine instead of 5-FU, a
commonly used agent, in combination with cisplatin for con-
current chemoradiotherapy in patients with locally advanced
SCCHN. In the current study, the clinical CR rate (78.4%),
locoregional control rate (72.6% at 2-year), and progression-free
survival rate (57.9% at 2 years) following treatment with the
present regimen, which can be administered on an outpatient
basis, were comparable with previous results reported for 5-FU
and platinum-based concurrent chemoradiotherapy, although the
follow-up period was relatively short to compare the survival rate
directly (Calais et al, 1999; Adelstein et al, 2000, 2003). For
example, concurrent chemotherapy with infusion of 5-FU and
cisplatin arm achieved a CR rate of 49.4% and 3-year overall
survival rate of 27% in a randomised study compared with
concurrent chemoradiotherapy with radiation therapy alone
(Adelstein et al, 2003).
Since the efficacy and favourable safety profile of capecitabine
have been clearly demonstrated in recent large phase III studies
comparing capecitabine with intravenous 5-FU plus leucovorin for
metastatic colorectal cancer (Hoff et al, 2001; Van Cutsem et al,
2001), capecitabine has been widely used in the treatment of breast
cancer, stomach cancer, and other solid tumours (Blum et al, 1999;
Kim et al, 2002, 2003). Capecitabine also offers a number of
potential advantages as a chemoradiosensitiser in concurrent
chemoradiotherapy. Daily administration mimicking the contin-
uous infusion of 5-FU can act as a radiosensitiser for every fraction
of radiotherapy. Furthermore, its mode of activation by TP and
radiotherapy concentrates it within tumour cells, raising the
prospect of better tumour control. Given these advantages, several
studies have demonstrated that concurrent chemoradiotherapy
using capecitabine, with a dose ranging from 800 to 825mgm
 2
b.i.d, in combination with cisplatin or oxaliplatin is effective and
has a low toxicity profile in the neoadjuvant setting of rectal cancer
or locally advanced oesophageal cancer (Rodel et al, 2003;
Hofheinz et al, 2005; Kim JC et al, 2005; Kim SB et al, 2005).
Oral mucositis and myelosuppression are the most serious
complications of concurrent chemoradiotherapy for SCCHN,
resulting in a reduced compliance to treatment or sometimes
mortality. In the present study, mucositis was the most common
adverse effect observed, with a grade 3 or 4 intensity in 67.6% of
the patients. In a randomised study by Calais et al (1999), the
incidence of grade 3 or 4 mucositis in concurrent chemora-
diotherapy with 5-FU and cisplatin was 71%, which was higher
than with radiotherapy only (39%). The incidence of mucositis was
not so different between chemoradiotherapy with capecitabine/
cisplatin and 5-FU/cisplatin. Meanwhile, grade 3 or 4 neutropenia
occurred only in two patients (5.4%), plus grade 3 febrile
neutropenia was observed in patient (2.7%) in the current study.
These incidences of haematologic toxicities were significantly
different from previous studies using 5-FU-containing regimens,
where the incidence of grade 3 or 4 leukopenia was 29–81%
(Vokes et al, 2000; Adelstein et al, 2003). Recently, taxanes, such as
paclitaxel and docetaxel, which exhibit activity against SCCHN, are
being increasingly used for concurrent chemoradiotherapy to
improve the treatment outcome (Kies et al, 2001; Tishler et al,
2002; Katori et al, 2004). Kies et al (2001) reported that
concomitant infusional paclitaxel and fluorouracil, oral hydro-
xyurea, and radiation therapy achieved a clinical CR rate of 69%, 3-
year locoregional control rate of 86%, and 3-year overall survival
rate of 60% in patients with locally advanced SCCHN. Thus, when
considering the high percentage of patients with a T4 and N2/3
disease in this study, the locoregional control rate and overall
survival seemed to be promising. However, 34% of the patients
experienced grade 3 or 4 leukopenia, and two patients (3%) died of
treatment-related toxicities. Therefore, taxane-based regimens
should be tested in a randomised trial and compared with a less
intensive concurrent regimen.
In conclusion, concurrent chemoradiotherapy with capecitabine
and cisplatin was found to be well tolerated and effective in
patients with locally advanced SCCHN. Accordingly, this regimen
can be regarded as an important chemoradiotherapy option for
advanced HNSCC, although long-term follow-up is needed to
evaluate the late treatment failure and complications.
Table 3 Acute toxic effects (N¼37)
Grade (% of patients)
123 4
Grade
3/4 (%)
Haematologic
Anaemia 13 (35.1) 6 (16.2) 2 (5.4) 1 (2.7) 8.1
Leukopenia 6 (16.2) 8 (21.6) 2 (5.4) 1 (2.7) 8.1
Neutropenia 7 (18.9) 6 (16.2) 1 (2.7) 1 (2.7) 5.4
Thrombocytopenia 12 (32.4) 2 (5.4) 1 (2.7) 2.7
Febrile neutropenia 1 (2.7) 2.7
Nonhaematologic
Nausea 11 (29.7) 12 (32.4) 5 (13.5) 1 (2.7) 16.2
Vomiting 9 (24.3) 10 (27.0) 3 (8.1) 8.1
Mucositis 2 (5.4) 10 (27.0) 17 (45.9) 8 (21.6) 67.6
Dermatitis (in-field) 3 (8.1) 12 (32.4) 7 (18.9) 2 (5.4) 24.3
Diarrhoea 4 (10.8) 3 (8.1) 1 (2.7)
Hand–foot syndrome 12 (32.4) 4 (10.8)
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